0.10Open0.10Pre Close0 Volume133 Open Interest17.50Strike Price0.00Turnover302.07%IV95.56%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.0723Delta0.0382Gamma90.00Leverage Ratio-0.0359Theta0.0001Rho6.51Eff Leverage0.0016Vega
Stoke Therapeutics Stock Discussion
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome
In the rapidly evolving world of biotechnology, companies like Stoke Therapeutics are pioneering groundbreaking treatments that could potentially change the lives of patients with severe diseases. The recent buzz surrounding Stoke Therapeutics, particularly their work on an anti-epilepsy drug, STK-001, underscores the transformative potential of RNA-based therapies in addres...
No comment yet